Navigation Links
Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY
Date:10/19/2009

statements involve risks and uncertainties, and actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to: (i) the risk that we may not have sufficient funds to operate our business; (ii) our success in attracting new business and retaining existing clients and projects; (iii) the size, duration and timing of clinical trials we are currently managing may change unexpectedly; (iv) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues and cash-on-hand to decline unexpectedly; (v) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (vi) outsourcing trends in the pharmaceutical, biotechnology and medical device industries; (vii) the ability to maintain profit margins in a competitive marketplace; (viii) our ability to attract and retain qualified personnel; (ix) the sensitivity of our business to general economic conditions; (x) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and prices; (xi) announced awards received from existing and potential customers are not definitive until fully negotiated contracts are executed by the parties; (xii) our backlog may not be indicative of future results and may not generate the revenues expected; and (xiii) uncertainties regarding the availability of additional capital and continued listing of our common stock on Nasdaq. You should not place undue reliance on any forward-looking statement. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events. Please refer to the section entitled "Risk Factors" in the Company Annual Report on Form 10-K for the year ended December 31
'/>"/>
SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win;
2. Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing
3. Encorium Reports Second Quarter 2009 Financial Results
4. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
5. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
6. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
7. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
8. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
9. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
10. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
11. Encorium Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Willow Grove, PA (PRWEB) August 28, 2014 ... talent, and create a culture that will allow individuals ... that are becoming increasingly important for employers looking to ... life science industries are embracing this trend, as the ... the fabric of a company, which will have real ...
(Date:8/28/2014)... 2014  Armetheon, Inc. ( www.armetheon.com ), a ... late-stage cardiovascular drug candidates, today announced that it ... of financing. The Series A round was co-led ... participation from investors that included Atheneos Capital and ... Larry Hsu , the founder of Impax Laboratories. ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Earlier this ... University in partnership with the U.S. Air Force ... biofuel. The results indicated that this type of fuel ... feedstock and will be important to America’s Eco friendly ... now has a mandate to become independent of foreign ...
(Date:8/27/2014)... August 27, 2014 Varian Medical Systems ... its current Salt Lake City manufacturing facility and allow ... Utah to ultimately create 1,000 new full time jobs ... , “Utah is home to hardworking people with immense ... credited with Varian’s success in the manufacturing of our ...
Breaking Biology Technology:Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3
... 15, 2011 This evening, Novo Nordisk awarded sponsorships ... support programs that educate people living with type 2 ... reduce the risk of long-term diabetes related complications. The ... program – a new initiative that aims to promote ...
... 15, 2011 Roka Bioscience announced today that the ... certification of the Listeria Detection Assay. This evaluation is ... (AOAC-RI) certification of methods used in the food safety ... laboratory and monitored by AOAC. The internal portion of ...
... /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP ... pharmaceutical and biotechnology research and development outsourcing company, ... leading Chinese pharmaceutical company, today announced that Shanghai ... and Hengrui have entered into a strategic partnership ...
Cached Biology Technology:Novo Nordisk and Atlanta Area Organizations Partner on Diabetes Education Programs 2Novo Nordisk and Atlanta Area Organizations Partner on Diabetes Education Programs 3Roka Bioscience Initiates External Trial for AOAC Certification 2ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development 2ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development 3
(Date:8/29/2014)... has been known about what genetic changes transform wild ... one of whom is a University of Montana assistant ... controlling the development of the brain and the nervous ... was published Aug. 28 in Science and ... at http://www.sciencemag.org/ ., The domestication of animals and ...
(Date:8/29/2014)... researchers explored the type and number of connections in ... plays on robustness in a study published in ... found that the assortativity signature contributes to a network,s ... that varying the out-out assortativity of TFN models has ... the other three types of assortativity," said Dov A. ...
(Date:8/29/2014)... as the prolific bloomer Emiliania huxleyi , can ... The finding contradicts the common view that E. ... scarce supplies of thiamine in the ocean to survive. ... the ocean," says CIFAR Senior Fellow Alexandra Worden ... with CIFAR fellows John Archibald (Dalhousie University), ...
Breaking Biology News(10 mins):New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Assortativity signatures of transcription factor networks contribute to robustness 2Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3
... Smart Search & Match,the leading provider of high-performance ... has joined the company as Product Marketing Manager. ... 15 years of product and marketing management,experience to ... many high-tech products and solutions worldwide. He has ...
... 2008 An international research team led by Tim ... the director of the School of Medicine,s Center for ... alternative splicing, the process by which single genes produce ... that curing the more than half of genetic diseases ...
... what they think may be a basic recipe for ... stem cells from essentially any mammal, including cows, pigs ... December 26th issue of the journal Cell , ... demonstrated to work in mice earlier this year, which ...
Cached Biology News:Case Western Reserve finds mechanism underlying alt. splicing of premessenger RNA into messenger RNA 2Case Western Reserve finds mechanism underlying alt. splicing of premessenger RNA into messenger RNA 3Recipe for capturing authentic embryonic stem cells may apply to any mammal, study suggests 2Recipe for capturing authentic embryonic stem cells may apply to any mammal, study suggests 3
... Storage: The kit is stable for 12 months ... contents of the kit cold. , ,Principle: ... silica-gel based membrane which selectively adsorbs up to ... specialized binding buffers. Nucleotides, oligos ( , ,Application: ...
The Econo gradient pump rack is a preassembled rack that is used to hold the components of the Econo gradient pump kits....
... Leu DAP FLISP Assay with FAM-Labeled ... nm) • Accurately measure serine protease ... permeabilization • B-Bridge's FLISP Kits utilize ... proteases (FLISPs) to measure chymotrypsin-like activity ...
... instrument is the cycler that revolutionized ... uniformity and swappable blocks ensure consistent ... This rugged machine is more than ... for new features and upgrades as ...
Biology Products: